share_log

Roth Capital Reinstates Buy on Rain Oncology, Announces $21 Price Target

Benzinga Real-time News ·  Jan 31, 2023 08:34

Roth Capital analyst Kumaraguru Raja reinstates Rain Oncology (NASDAQ:RAIN) with a Buy and announces $21 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment